Brief Communication | Published:

A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation

Nature Chemical Biology volume 6, pages 264266 (2010) | Download Citation

This article has been updated

Abstract

We describe a new method for producing homogeneous eukaryotic N-glycoproteins. The method involves the engineering and functional transfer of the Campylobacter jejuni glycosylation machinery in Escherichia coli to express glycosylated proteins with the key GlcNAc-Asn linkage. The bacterial glycans were then trimmed and remodeled in vitro by enzymatic transglycosylation to fulfill a eukaryotic N-glycosylation. It provides a potentially general platform for producing eukaryotic N-glycoproteins.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 18 March 2010

    In the version of this article initially published online, an extra blue square corresponding to a GlcNAc monomer was shown in the transglycosylation step in Figure 1 and the Graphical Abstract. Also, panels g and h of Figure 2 were mistakenly swapped. The errors have been corrected for the print, PDF and HTML versions of this article.

References

  1. 1.

    Chem. Rev. 96, 683–720 (1996).

  2. 2.

    & Science 291, 2364–2369 (2001).

  3. 3.

    , & Chem. Rev. 109, 131–163 (2009).

  4. 4.

    & Nat. Chem. Biol. 5, 206–215 (2009).

  5. 5.

    & Chem. Soc. Rev. 36, 1227–1238 (2007).

  6. 6.

    , , , & Mol. Microbiol. 32, 1022–1030 (1999).

  7. 7.

    et al. J. Biol. Chem. 277, 42530–42539 (2002).

  8. 8.

    et al. Science 298, 1790–1793 (2002).

  9. 9.

    et al. Science 314, 1148–1150 (2006).

  10. 10.

    , , , & J. Am. Chem. Soc. 127, 9692–9693 (2005).

  11. 11.

    , , & Org. Lett. 8, 3081–3084 (2006).

  12. 12.

    , & J. Am. Chem. Soc. 130, 13790–13803 (2008).

  13. 13.

    et al. Biochemistry 47, 10294–10304 (2008).

  14. 14.

    et al. J. Biol. Chem. 283, 4469–4479 (2008).

  15. 15.

    et al. J. Am. Chem. Soc. 131, 2214–2223 (2009).

  16. 16.

    et al. Proc. Natl. Acad. Sci. USA 102, 3016–3021 (2005).

  17. 17.

    et al. Proc. Natl. Acad. Sci. USA 103, 7088–7093 (2006).

  18. 18.

    et al. EMBO J. 25, 967–976 (2006).

  19. 19.

    , , & J. Bacteriol. 189, 2618–2628 (2007).

  20. 20.

    et al. EMBO J. 25, 1957–1966 (2006).

  21. 21.

    & Biochemistry 48, 2807–2816 (2009).

  22. 22.

    Biotechnol. Prog. 21, 11–16 (2005).

  23. 23.

    et al. Science 320, 373–376 (2008).

  24. 24.

    et al. Int. J. Cancer 122, 2405–2413 (2008).

  25. 25.

    & Nat. Biotechnol. 23, 1126–1136 (2005).

Download references

Acknowledgements

We thank members of the Aebi and Wang labs for fruitful discussions. This work was supported in part by the Swiss National Science Foundation (grant 3100AQ-105541 to M.A.), the Eidgenössische Technische Hochschule Zurich and the US National Institutes of Health (grant GM080374 to L.-X.W.). We thank K. Takegawa (Kyushu University) for providing the pGEX-2T/Endo-A plasmid and K. Yamamoto (Kyoto University) for providing the pET23b-Endo-M plasmid, which were used to express the endo enzymes. F.S. and C. Lizak are members of the Zurich PhD Program in Molecular Life Sciences.

Author information

Affiliations

  1. Institute of Microbiology, Department of Biology, Eidgenössische Technische Hochschule (ETH) Zurich, Zurich, Switzerland.

    • Flavio Schwarz
    • , Benjamin L Schulz
    • , Christian Lizak
    • , Shin Numao
    •  & Markus Aebi
  2. Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

    • Wei Huang
    • , Cishan Li
    •  & Lai-Xi Wang
  3. Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

    • Wei Huang
    • , Cishan Li
    •  & Lai-Xi Wang
  4. Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Eidgenössische Technische Hochschule (ETH) Zurich, Zurich, Switzerland.

    • Alessandro Palumbo
    •  & Dario Neri

Authors

  1. Search for Flavio Schwarz in:

  2. Search for Wei Huang in:

  3. Search for Cishan Li in:

  4. Search for Benjamin L Schulz in:

  5. Search for Christian Lizak in:

  6. Search for Alessandro Palumbo in:

  7. Search for Shin Numao in:

  8. Search for Dario Neri in:

  9. Search for Markus Aebi in:

  10. Search for Lai-Xi Wang in:

Contributions

F.S. engineered the glycosylation pathway, characterized proteins and wrote the manuscript. W.H. trimmed and remodeled glycans and characterized products. C. Li remodeled glycans and characterized products. B.L.S. performed preliminary MS analyses of glycosylated AcrA. C. Lizak engineered the CH2 domain. A.P. characterized the F8 protein. S.N. conceived the original idea and performed preliminary experiments. D.N. developed F8 and supervised the research. M.A. supervised the research and wrote the manuscript. L.-X.W. conceived the original idea, supervised the research and wrote the manuscript. All authors contributed to editing the manuscript.

Competing interests

D.N. is a co-founder and shareholder of Philogen, the company that owns the F8 antibody.

Corresponding authors

Correspondence to Markus Aebi or Lai-Xi Wang.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Methods, Supplementary Results, and Supplementary Figures 1–9

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nchembio.314

Further reading